Patents by Inventor Pascal Rigollier

Pascal Rigollier has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • COMPOUNDS AND COMPOSITIONS AS Sppl2a INHIBITORS
    Publication number: 20230365571
    Abstract: The present invention relates to tricyclic compounds comprising a diazepinone moiety which are effective in inhibiting Sppl2a (signal peptide peptidase like protease 2a), to pharmaceutical compositions containing such inhibitors, and to methods of using such inhibitors and compositions.
    Type: Application
    Filed: September 15, 2021
    Publication date: November 16, 2023
    Inventors: Trixi Brandl, Claus Ehrhardt, Robert Epple, Christian Markert, Pascal Rigollier, Juraj Velcicky
  • Pyrazolyl derivatives useful as anti-cancer agents
    Patent number: 11702409
    Abstract: The present invention provides a compound of formula (I) or a stereoisomer thereof, or an atropisomer thereof, or a pharmaceutically acceptable salt thereof, or a pharmaceutically acceptable salt of a stereoisomer thereof, or a pharmaceutically acceptable salt of an atropisomer thereof; a method for manufacturing said compound, and its therapeutic uses. The present invention further provides a combination of pharmacologically active agents and a pharmaceutical composition comprising said compound.
    Type: Grant
    Filed: December 17, 2020
    Date of Patent: July 18, 2023
    Assignee: NOVARTIS AG
    Inventors: Simona Cotesta, Marc Gerspacher, Catherine Leblanc, Edwige Liliane Jeanne Lorthiois, Bo Liu, Rainer Machauer, Robert Mah, Christophe Mura, Pascal Rigollier, Nadine Schneider, Stefan Stutz, Andrea Vaupel, Nicolas Warin, Rainer Wilcken
  • Pyrazolyl derivatives useful as anti-cancer agents
    Publication number: 20220363670
    Abstract: The present invention provides a compound of formula (I) or a stereoisomer thereof, or an atropisomer thereof, or a pharmaceutically acceptable salt thereof, or a pharmaceutically acceptable salt of a stereoisomer thereof, or a pharmaceutically acceptable salt of an atropisomer thereof; a method for manufacturing said compound, and its therapeutic uses. The present invention further provides a combination of pharmacologically active agents and a pharmaceutical composition comprising said compound.
    Type: Application
    Filed: December 17, 2020
    Publication date: November 17, 2022
    Inventors: Simona Cotesta, Marc Gerspacher, Catherine Leblanc, Edwige Liliane Jeanne Lorthiois, Bo Liu, Rainer Machauer, Robert Mah, Christophe Mura, Pascal Rigollier, Nadine Schneider, Stefan Stutz, Andrea Vaupel, Nicolas Warin, Rainer Wilcken
  • ArylSulfonamide-based matrix metalloprotease inhibitors
    Patent number: 9822092
    Abstract: The present invention provides a compound of formula (I): said compound is inhibitor of MMP-2, and/or MMP-8, and/or MMP-9, and/or MMP-12 and/or MMP-13, and thus can be employed for the treatment of a disorder or disease characterized by abnormal activity of MMP-2, and/or MMP-8, and/or MMP-9, and/or MMP-12 and/or MMP-13. Accordingly, the compound of formula (I) can be used in treatment of disorders or diseases mediated by MMP-2, and/or MMP-8, and/or MMP-9, and/or MMP-12, and/or MMP-13. Finally, the present invention also provides a pharmaceutical composition.
    Type: Grant
    Filed: October 7, 2014
    Date of Patent: November 21, 2017
    Assignee: NOVARTIS AG
    Inventors: Claus Ehrhardt, Leslie Wighton McQuire, Pascal Rigollier, Olivier Rogel, Michael David Shultz, Ruben Alberto Tommasi
  • Organic compounds and their uses
    Patent number: 9206232
    Abstract: The present application describes organic compounds of Formula (II) that are useful for the treatment, prevention and/or amelioration of human diseases.
    Type: Grant
    Filed: August 18, 2014
    Date of Patent: December 8, 2015
    Assignee: Novartis AG
    Inventors: Trixi Brandl, Prakash Raman, Pascal Rigollier, Mohindra Seepersaud, Oliver Simic
  • Arylsulfonamide based matrix metalloprotease inhibitors
    Patent number: 8975439
    Abstract: The present invention provides a compound of formula (I): said compound is inhibitor of MMP-2, and/or MMP-8, and/or MMP-9, and/or MMP-12 and/or MMP-13, and thus can be employed for the treatment of a disorder or disease characterized by abnormal activity of MMP-2, and/or MMP-8, and/or MMP-9, and/or MMP-12 and/or MMP-13. Accordingly, the compound of formula (I) can be used in treatment of disorders or diseases mediated by MMP-2, and/or MMP-8, and/or MMP-9, and/or MMP-12, and/or MMP-13. Finally, the present invention also provides a pharmaceutical composition.
    Type: Grant
    Filed: November 30, 2012
    Date of Patent: March 10, 2015
    Assignee: Novartis AG
    Inventors: Ruben Alberto Tommasi, Michael David Shultz, Leslie Wighton McQuire, Pascal Rigollier, Olivier Rogel, Claus Ehrhardt
  • ORGANIC COMPOUNDS AND THEIR USES
    Publication number: 20140357551
    Abstract: The present application describes organic compounds of Formula (II) that are useful for the treatment, prevention and/or amelioration of human diseases.
    Type: Application
    Filed: August 18, 2014
    Publication date: December 4, 2014
    Applicant: Novartis AG
    Inventors: Trixi Brandl, Prakash Raman, Pascal Rigollier, Mohindra Seepersaud, Oliver Simic
  • Peptidomimetic sulfamide compounds and antiviral uses thereof
    Patent number: 8840878
    Abstract: The present application describes organic compounds that are useful for the treatment, prevention and/or amelioration of human diseases.
    Type: Grant
    Filed: September 13, 2012
    Date of Patent: September 23, 2014
    Assignee: Novartis AG
    Inventors: Trixi Brandl, Prakash Raman, Pascal Rigollier, Mohindra Seepersaud, Oliver Simic
  • Peptidomimetic sulfamide compounds and antiviral uses thereof
    Patent number: 8613914
    Abstract: The present application describes organic compounds that are useful for the treatment, prevention and/or amelioration of human diseases.
    Type: Grant
    Filed: September 13, 2012
    Date of Patent: December 24, 2013
    Assignee: Novartis AG
    Inventors: Trixi Brandl, Prakash Raman, Pascal Rigollier, Mohindra Seepersaud, Oliver Simic
  • Derivatised proline containing peptide compounds as protease inhibitors
    Patent number: 8512690
    Abstract: The present application describes organic compounds that are useful for the treatment, prevention and/or amelioration of human diseases.
    Type: Grant
    Filed: April 7, 2010
    Date of Patent: August 20, 2013
    Assignee: Novartis AG
    Inventors: Trixi Brandl, Prakash Raman, Pascal Rigollier, Mohindra Seepersaud, Oliver Simic
  • Organic compounds and their uses
    Patent number: 8445527
    Abstract: The present invention provides a method of treating a HCV infection in a subject in need thereof by administering a compound of Formula I: or pharmaceutically acceptable salts thereof or stereoisomers thereof.
    Type: Grant
    Filed: May 22, 2012
    Date of Patent: May 21, 2013
    Assignee: Novartis AG
    Inventors: Michael Patane, Prakash Raman, David Thomas Parker, Jiping Fu, Branko Radetich, Mohindra Seepersaud, Aregahegn Yifru, Rui Zheng, Trixi Brandl, Francois Lenoir, Pascal Rigollier, Oliver Simic
  • Arylsulfonamide based matrix metalloprotease inhibitors
    Patent number: 8362063
    Abstract: The present invention provides a compound of formula (I): said compound is inhibitor of MMP-2, and/or MMP-8, and/or MMP-9, and/or MMP-12 and/or MMP-13, and thus can be employed for the treatment of a disorder or disease characterized by abnormal activity of MMP-2, and/or MMP-8, and/or MMP-9, and/or MMP-12 and/or MMP-13. Accordingly, the compound of formula (I) can be used in treatment of disorders or diseases mediated by MMP-2, and/or MMP-8, and/or MMP-9, and/or MMP-12, and/or MMP-13. Finally, the present invention also provides a pharmaceutical composition.
    Type: Grant
    Filed: May 29, 2012
    Date of Patent: January 29, 2013
    Assignee: Novartis AG
    Inventors: Ruben Alberto Tommasi, Michael Shultz, Leslie Wighton McQuire, Pascal Rigollier, Olivier Rogel, Claus Ehrhardt
  • ArylSulfonamide Based Matrix Metalloprotease Inhibitors
    Publication number: 20120258954
    Abstract: The present invention provides a compound of formula (I): said compound is inhibitor of MMP-2, and/or MMP-8, and/or MMP-9, and/or MMP-12 and/or MMP-13, and thus can be employed for the treatment of a disorder or disease characterized by abnormal activity of MMP-2, and/or MMP-8, and/or MMP-9, and/or MMP-12 and/or MMP-13. Accordingly, the compound of formula (I) can be used in treatment of disorders or diseases mediated by MMP-2, and/or MMP-8, and/or MMP-9, and/or MMP-12, and/or MMP-13. Finally, the present invention also provides a pharmaceutical composition.
    Type: Application
    Filed: May 29, 2012
    Publication date: October 11, 2012
    Applicant: NOVARTIS AG
    Inventors: Claus Ehrhardt, Leslie Wighton McQuire, Pascal Rigollier, Olivier Rogel, Michael Shultz, Ruben Alberto Tommasi
  • ORGANIC COMPOUNDS AND THEIR USES
    Publication number: 20120231998
    Abstract: The present application describes organic compounds that are useful for the treatment, prevention and/or amelioration of human diseases.
    Type: Application
    Filed: May 22, 2012
    Publication date: September 13, 2012
    Inventors: Trixi Brandl, Jiping Fu, Francois Lenoir, David Thomas Parker, Michael Patane, Branko Radetich, Prakash Raman, Pascal Rigollier, Mohindra Seepersaud, Oliver Simic, Aregahegn Yifru, Rui Zheng
  • Organic compounds and their uses
    Patent number: 8222425
    Abstract: The present application describes organic compounds that are useful for the treatment, prevention and/or amelioration of human diseases.
    Type: Grant
    Filed: July 19, 2011
    Date of Patent: July 17, 2012
    Assignee: Novartis AG
    Inventors: Shawn D. Britt, Lech Andrzej Ciszewski, Jiping Fu, Subramanian Karur, Yugang Liu, Peichao Lu, David Thomas Parker, Mahavir Prashad, Prakash Raman, Pascal Rigollier, Mohindra Seepersaud, Aregahegn Yifru, Rui Zheng
  • Arylsulfonamide-based matrix metalloprotease inhibitors
    Patent number: 8222424
    Abstract: The present invention provides a compound of formula (I): said compound is inhibitor of MMP-2, and/or MMP-8, and/or MMP-9, and/or MMP-12 and/or MMP-13, and thus can be employed for the treatment of a disorder or disease characterized by abnormal activity of MMP-2, and/or MMP-8, and/or MMP-9, and/or MMP-12 and/or MMP-13. Accordingly, the compound of formula (I) can be used in treatment of disorders or diseases mediated by MMP-2, and/or MMP-8, and/or MMP-9, and/or MMP-12, and/or MMP-13. Finally, the present invention also provides a pharmaceutical composition.
    Type: Grant
    Filed: March 23, 2009
    Date of Patent: July 17, 2012
    Assignee: Novartis AG
    Inventors: Claus Ehrhardt, Leslie Wighton McQuire, Pascal Rigollier, Olivier Rogel, Michael Shultz, Ruben Alberto Tommasi
  • Organic compounds and their uses
    Patent number: 8211932
    Abstract: The present application describes organic compounds of the Formula I that are useful for the treatment, prevention and/or amelioration of human diseases.
    Type: Grant
    Filed: September 10, 2010
    Date of Patent: July 3, 2012
    Assignee: Novartis AG
    Inventors: Michael Patane, Prakash Raman, David Thomas Parker, Jiping Fu, Branko Radetich, Mohindra Seepersaud, Aregahegn Yifru, Rui Zheng, Trixi Brandl, Francois Lenoir, Pascal Rigollier, Oliver Simic
  • Organic compounds and their uses
    Patent number: 8008263
    Abstract: The present application describes organic compounds that are useful for the treatment, prevention and/or amelioration of human diseases.
    Type: Grant
    Filed: October 10, 2008
    Date of Patent: August 30, 2011
    Assignee: Novartis AG
    Inventors: Shawn D. Britt, Lech Andrzej Ciszewski, Jiping Fu, Subramanian Karur, Yugang Liu, Peichao Lu, David Thomas Parker, Mahavir Prashad, Prakash Raman, Pascal Rigollier, Mohindra Seepersaud, Aregahegn Yifru, Rui Zheng
  • ORGANIC COMPOUNDS AND THEIR USES
    Publication number: 20110182850
    Abstract: The present application describes organic compounds that are useful for the treatment, prevention and/or amelioration of human diseases.
    Type: Application
    Filed: April 7, 2010
    Publication date: July 28, 2011
    Inventors: Trixi BRANDL, Prakash Raman, Pascal Rigollier, Mohindra Seepersaud, Oliver Simic
  • ARYLSULFONAMIDE-BASED MATRIX METALLOPROTEASE INHIBITORS
    Publication number: 20110014186
    Abstract: The present invention provides a compound of formula (I): said compound is inhibitor of MMP-2, and/or MMP-8, and/or MMP-9, and/or MMP-12 and/or MMP-13, and thus can be employed for the treatment of a disorder or disease characterized by abnormal activity of MMP-2, and/or MMP-8, and/or MMP-9, and/or MMP-12 and/or MMP-13. Accordingly, the compound of formula (I) can be used in treatment of disorders or diseases mediated by MMP-2, and/or MMP-8, and/or MMP-9, and/or MMP-12, and/or MMP-13. Finally, the present invention also provides a pharmaceutical composition.
    Type: Application
    Filed: March 23, 2009
    Publication date: January 20, 2011
    Inventors: Claus Ehrhardt, Leslie Wighton McQuire, Pascal Rigollier, Olivier Rogel, Michael Shultz, Ruben Alberto Tommasi